Boehringer Ingelheim's Spiriva Respimat NDA for asthma accepted for review by FDA

4 November 2014

German family-owned drug major Boehringer Ingelheim has had its Spiriva Respimat (tiotropium bromide) inhalation spray New Drug Application accepted for review by the US Food and Drug Administration with respect to the treatment of asthma.

The drug is intended as a long-term, once-daily, add-on maintenance treatment of asthma for patients aged 12 years and over who remain symptomatic on at least inhaled corticosteroids. Spiriva Respimat is currently being studied to determine its efficacy and safety profile in treating asthma patients and is not presently approved for this indication.

It is currently approved for maintenance of bronchospasm associated with chronic obstructive pulmonary disease, and to reduce COPD exacerbations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK